RxDoctor Payments Data

Mahlet Tadele, MD

Internal Medicine · Bronx, NYNPI 1770731812

Payments from drug & device makers

$1,829in general payments, 2019–2025

Across 90 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$792
  • Viiv Healthcare Company$594
  • Gilead$180
  • Merck$131
  • Janssen Products, LP$100
  • AbbVie$32

What the payments were for

  • Food & beverage$1,70093%
  • Education$1287%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)44$792
Viiv Healthcare Company27$594
Gilead10$180
Merck7$131
Janssen Products, LP1$100
AbbVie1$32

How this compares

$1,829 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$143,329
Medicare patients
353
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala122$467,358
DescovyEmtricitabine/Tenofov Alafenam42$89,895
PrezcobixDarunavir/Cobicistat37$86,682
TivicayDolutegravir Sodium38$82,729
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$78,903
TriumeqAbacavir/Dolutegravir/Lamivudi15$54,428
IsentressRaltegravir Potassium12$22,524
Etravirine12$15,341
EliquisApixaban14$8,404
JardianceEmpagliflozin14$8,068
Combivent RespimatIpratropium/Albuterol Sulfate14$6,574
ErtapenemErtapenem Sodium13$5,351
SymbicortBudesonide/Formoterol Fumarate11$2,535
Daptomycin15$2,186
Darunavir12$1,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$180$557,253164 claims
Viiv Healthcare CompanyTivicay, Triumeq$594$137,15753 claims
Johnson & JohnsonPrezcobix$792$86,68237 claims
MerckIsentress$131$22,52412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →